{"id":515,"title":"China rewrites its regulatory framework for stem cell clinical translation","title_zh":"中国重构干细胞临床转化监管框架","url":"https://doi.org/10.1016/j.stem.2026.09.017","doi":"10.1016/j.stem.2026.09.017","pmid":null,"journal":"Cell Stem Cell","kind":"paper","lang":"en","published_at":"2026-11-01T00:00:00+00:00","fetched_at":"2026-11-08T03:45:21+00:00","authors":["Ruohan Feng","Xue Pang","Yi Hao","Tong Zhao","Yaojin Peng"],"primary_topic":"ethics-policy","topics":[{"slug":"ethics-policy","score":3.0,"hits":["regulatory"]}],"topic_score":3.0,"preference_score":0.0,"preference_labels":[],"llm_score":58.0,"final_score":66.0,"score_dims":{"novelty":55,"rigor":30,"impact":60,"relevance":35,"translation":40},"recommend_reason":"值得浏览，可了解中国干细胞临床转化监管变化及其治理含义；但原文无摘要、非辅助生殖核心内容，暂不作为必读。","keywords":["干细胞","临床转化","监管框架","中国","伦理治理","政策"],"selected":1,"story_id":220,"llm_provider":"deepseek","llm_model":"deepseek-flash","llm_effort":"low","source_key":"crossref-cns","source_name":"Crossref · CNS 与大子刊新上线（领域过滤）","source_tier":1,"mention_count":1,"has_interpretation":false,"journal_key":"cell-stem-cell","journal_tier":"cns-sub","journal_if":19.8,"is_mock":false,"summary_zh":"该文为Cell Stem Cell上线文章，讨论中国干细胞临床转化监管框架的调整，涉及监管规则、临床转化路径与治理要求；因无摘要，无法核实具体政策条款、分析方法和证据来源。对干细胞临床转化及胚胎/生殖相关研究治理有参考价值，但与辅助生殖临床核心关联有限。","summary":"","interpretation_basis":null,"fulltext_status":null,"interpretation":null,"fulltext":{"available":false,"status":null,"reason":"尚未抓取全文（未入选、分数未达阈值，或还没跑 fulltext 步骤）","pmcid":null,"license":null,"chars":0,"source":null,"fetched_at":null}}